Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Ain Pharmaciez to Become No. 1 Dispensing Pharmacy Operator: Report
January 22, 2001
- SBS, GSK Copromote Antidepressant
January 22, 2001
- Revised GPMSP to Be Enforced from October 1
January 22, 2001
- OTC NEWS IN BRIEF
January 22, 2001
- Santen Markets Betimol for Glaucoma in the US
January 22, 2001
- LDP Hashimoto Group Proposes Copayment of 10% or More for Elderly Healthcare
January 22, 2001
- DIAGNOSTIC NEWS IN BRIEF
January 22, 2001
- Life Science Units of Tomen, Nichimen to Merge into New Company
January 22, 2001
- CPAC Members Fail to Form Consensus on Production, Supply of Blood Preparations
January 22, 2001
- MEDICAL DEVICE NEWS IN BRIEF
January 22, 2001
- abbreviation
January 15, 2001
- Growth of Morphine Consumption Slows Down
January 15, 2001
- Welfide: Business Forecasts Affected by Transfer of Business, Shares
January 15, 2001
- REGULATORY NEWS IN BRIEF -1-
January 15, 2001
- Changing OTC Business Strategy, Priority Shifts to Volume Retailers
January 15, 2001
- Welfide Transfers Infusion Fluid Business to Otsuka Pharmaceutical Factory, Inc
January 15, 2001
- OTC news on brief
January 15, 2001
- Suntory, Taisho to Codevelop SUN N8075 for Cerebral Infarction
January 15, 2001
- Sankyo, Mochida Tie Up with Riken
January 15, 2001
- Tanabe Licenses Out TR-14035 to SmithKline Beecham
January 15, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…